Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data

Anavex Life Sciences Announces ANAVEX®2-73 Meets Primary and Secondary Endpoints in Clinical Trial

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims

Anavex Life Sciences Presents Proof of Concept Controlled Phase 2 Clinical Trial Data

Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Trial

Anavex Life Sciences Announces Completion of ANAVEX®2-73 U.S. Phase 2 Rett Syndrome Clinical Trial

Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 for Alzheimer’s

First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine)

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 U.S Phase 2 Trial

Anavex Life Sciences Receives Approval from Health Canada & UK MHRA Expanding Phase 2b/3 ANAVEX®2-73